Inozyme Pharma, a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.